AgomAb Therapeutics NV (AGMB)
NasdaqGS · USD · Healthcare · Biotechnology
$8.57 (-5.30%) as of
Key statistics
- Market cap
- 422.06M
- Forward P/E
- -4.23
- EPS (TTM)
- -2.08
- Dividend yield
- 0.00%
- 52-week range
- 7.92 – 17.82
- Profit margin
- 0.00%
- Analyst target
- $37.67
- Volume
- 73.65k
About AgomAb Therapeutics NV
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Antwerp, Belgium
- Employees
- 62
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.